ReviewFrontiers in pharmacology2026
Emerging roles of lipocalin-2-mediated neuroimmune interactions in chronic pain and itch.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroimmune interactions serve as a core regulatory node of chronic pain and pruritus and a key target for clinical intervention. Lipocalin-2 (LCN2), a member of the lipocalin superfamily, is a multifunctional protein widely expressed in various tissues and cells. LCN2 exerts diverse biological effects by regulating iron metabolism, mediating inflammatory responses, and participating in signal transduction pathways. In recent years, accumulating evidence has indicated that LCN2 plays a crucial role in the pathogenesis of chronic pain and pruritus through neuroinflammation, neuron-glia interactions, and modulation of neural signaling. In chronic pain, LCN2 contributes to the development and maintenance of inflammatory pain, neuropathic pain, morphine tolerance, and thalamic pain by disrupting iron homeostasis, inducing oxidative stress, and promoting central sensitization. For chronic pruritus, LCN2 modulates the excitability of pruritus-related neurons via pathways such as the IL-6/STAT3 axis, and participates in the pathological processes of pruritus in allergic contact dermatitis, xerosis, atopic dermatitis, and psoriasis. This review summarizes the structural characteristics, physiological functions of LCN2, and its specific mechanisms in regulating chronic pain and pruritus, and further discusses the potential therapeutic value of targeting LCN2, aiming to provide a theoretical basis for the development of novel interventions for chronic pain and pruritus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.